BBOT
BridgeBio Oncology Therapeutics Inc. NASDAQ Listed Aug 12, 2025$8.33
After hrs
$8.33
+0.00%
Mkt Cap $667.3M
52w Low $8.00
4.8% of range
52w High $14.87
50d MA $9.19
200d MA $10.85
P/E (TTM)
-1.9x
EV/EBITDA
-0.1x
P/B
0.6x
Debt/Equity
0.0x
ROE
-32.6%
P/FCF
-3.4x
RSI (14)
—
ATR (14)
—
Beta
0.51
50d MA
$9.19
200d MA
$10.85
Avg Volume
309.2K
About
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.63 | -0.49 | +22.6% | 9.89 | +5.7% | +5.4% | +4.2% | +3.0% | +1.0% | -7.7% | — |
| Nov 12, 2025 | AMC | -0.41 | -1.03 | -151.2% | 12.63 | +0.4% | -2.0% | +3.9% | +8.7% | +6.7% | +0.4% | — |
| Aug 1, 2025 | AMC | — | 0.04 | — | 10.43 | +1.8% | -8.9% | -12.3% | -5.2% | -4.1% | -3.5% | — |
| May 15, 2025 | AMC | — | -0.02 | — | 10.85 | +0.2% | +0.0% | +0.0% | +0.0% | -0.3% | -0.3% | — |
| Mar 11, 2025 | AMC | — | 0.12 | — | 10.70 | +0.0% | +0.2% | +0.8% | +0.7% | +0.5% | +0.5% | — |
| Nov 14, 2024 | AMC | — | 0.10 | — | 10.53 | +0.3% | +0.5% | -1.0% | -1.0% | -1.0% | -1.0% | — |
| Aug 14, 2024 | AMC | — | 0.09 | — | 10.40 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -0.1% | — |
| May 15, 2024 | AMC | — | 0.08 | — | 10.34 | +0.0% | +0.0% | +0.0% | +0.0% | -0.9% | -0.9% | — |
| Dec 31, 2023 | AMC | — | -0.00 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | — | -0.00 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.89 | $10.45 | +5.7% | +5.4% | +4.2% | +3.0% | +1.0% | -7.7% |
| Dec 11 | Wedbush | Maintains | Outperform → Outperform | — | $12.88 | $12.98 | +0.8% | -0.3% | -2.3% | -6.8% | -8.0% | -11.3% |
| Nov 25 | Wedbush | Maintains | Outperform → Outperform | — | $12.29 | $12.44 | +1.2% | +0.6% | -0.9% | +0.2% | -0.7% | -7.6% |
| Nov 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.63 | $12.68 | +0.4% | -2.0% | +3.9% | +8.7% | +6.7% | +0.4% |
Recent Filings
8-K · 7.01
! Medium
BridgeBio Oncology Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
BridgeBio Oncology announced leadership transitions on April 22, 2026, which could signal strategic shifts affecting company direction and investor confidence.
Apr 23
8-K
Unknown — 8-K Filing
A new board member's indemnification agreement signals BBOT is protecting leadership from litigation costs, which could indicate either standard governance practices or anticipated legal risks investors should monitor.
Mar 26
8-K
BridgeBio Oncology Therapeutics, Inc. -- 8-K Filing
BridgeBio Oncology Therapeutics (BBOT) reported 2025 results and announced clinical readouts expected in H2 2026 across its three RAS pathway inhibitor programs, creating upcoming catalysts for investors.
Mar 5
Data updated apr 24, 2026 8:44pm
· Source: massive.com